BioCentury
ARTICLE | Company News

Seattle Genetics, Astellas deal

July 15, 2013 7:00 AM UTC

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-15ME. Agensys, which received an undisclosed exercise payment, submitted an IND for a Phase I trial of the antibody-drug conjugate (ADC) targeting SLIT and NTRK-like family member 6 (SLITRK6). The companies said SLITRK6 has expressed preclinical antitumor activity in models of bladder and lung cancer. Under the 2007 deal that combines Seattle Genetics' ADC technology and Agensys' antibodies, Seattle Genetics is eligible for fees, milestones and mid-single digit royalties on compounds developed and commercialized solely by Agensys. The companies will share costs and profits equally for compounds developed together. ...